Episode
EP Edge Journal Watch Issue 10, February 2026: Pulsed Field Ablation Durability, AF Ablation Outcomes, Wearable AF Detection, ICD and VT Insights
- Podcast
- EP Edge Journal Watch
- Published
- Feb 9, 2026
- Duration seconds
- 1546
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/a0a815f2
Actions
POST https://stenobird.com/v1/public/podcasts/ep-edge-journal-watch-7561379/episodes/ep-edge-journal-watch-issue-10-february-2026-pulsed-field-ablation-durability-af-ablation-outcomes-wearable-af-detection-icd-and-vt-insights/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/ep-edge-journal-watch-7561379/ep-edge-journal-watch-issue-10-february-2026-pulsed-field-ablation-durability-af-ablation-outcomes-wearable-af-detection-icd-and-vt-insights.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
EP Edge Journal Watch: Feb 2026 Issue 10 In this episode of EP Edge Journal Watch , we examine the latest developments shaping the future of cardiac electrophysiology , with a focus on pulsed field ablation durability, atrial fibrillation ablation outcomes, wearable AF detection, ventricular tachycardia ablation endpoints, autonomic modulation, and ICD patient outcomes . Pulsed field ablation has rapidly transformed AF ablation due to its safety and efficiency, but long-term success depends on durable pulmonary vein isolation. We explore how next-generation catheter architecture, electrode geometry, and tissue contact optimization are redefining durability and advancing the effectiveness of catheter ablation for atrial fibrillation. This episode also highlights the expanding understanding that atrial fibrillation is driven not only by electrical triggers but also by systemic metabolic and autonomic factors . We discuss how metabolic therapies, including GLP-1 receptor agonists, may improve long-term rhythm control after ablation by modifying atrial substrate and inflammation. In parallel, wearable technologies such as smartwatches are accelerating AF detection , enabling earlier diagnosis of asymptomatic atrial fibrillation and fundamentally changing screening, referral, and management pathways for electrophysiologists and cardiologists. Beyond atrial fibrillation, we explore emerging advances in cardioneuroablation as a precision therapy for functional bradycardia and reflex syncope , the profound clinical impact of mental health disorders on outcomes following ICD implantation , and the ongoing challenges in defining meaningful success metrics in ventricular tachycardia ablation . We also examine the growing importance of sustainability, safety, and regulatory oversi…